Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Research & Development (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Research & Development data on record, last reported at $2.1 million in Q2 2025.

  • For Q2 2025, Research & Development fell 2.68% year-over-year to $2.1 million; the TTM value through May 2025 reached $8.3 million, down 3.7%, while the annual FY2025 figure was $8.3 million, 3.7% down from the prior year.
  • Research & Development reached $2.1 million in Q2 2025 per LFCR's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.3 million in Q1 2022 and bottomed at $443000.0 in Q1 2021.
  • Average Research & Development over 5 years is $2.0 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Research & Development: tumbled 83.87% in 2021, then surged 408.8% in 2022.
  • A 5-year view of Research & Development shows it stood at $1.9 million in 2021, then grew by 14.12% to $2.1 million in 2022, then dropped by 0.94% to $2.1 million in 2023, then decreased by 8.29% to $1.9 million in 2024, then increased by 9.3% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $2.1 million in Q2 2025, $2.0 million in Q1 2025, and $1.9 million in Q4 2024.